Check-Cap (NASDAQ:CHEK) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a report issued on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

CHEK stock opened at $1.63 on Friday. Check-Cap has a fifty-two week low of $1.61 and a fifty-two week high of $4.59. The stock’s 50 day simple moving average is $1.90 and its 200 day simple moving average is $2.11. The company has a market cap of $9.54 million, a P/E ratio of -0.54 and a beta of 0.39.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.